The association between metformin use and oncologic outcomes among surgically treated diabetic patients with localized renal cell carcinoma

Abstract Introduction Metformin inhibits renal cell carcinoma (RCC) cell proliferation both in vitro and in vivo; however, clinical data regarding the effect of metformin in patients with RCC are lacking. We evaluated the association of metformin use with outcomes among patients with surgically trea...

Full description

Saved in:
Bibliographic Details
Published in:Urologic oncology 2015-02, Vol.33 (2), p.67.e15-67.e23
Main Authors: Psutka, Sarah P., M.D, Boorjian, Stephen A., M.D, Lohse, Christine M., M.S, Stewart, Suzanne B., M.D, Tollefson, Matthew K., M.D, Cheville, John C., M.D, Leibovich, Bradley C., M.D, Thompson, R. Houston, M.D
Format: Article
Language:English
Subjects:
Aged
Carcinoma, Renal Cell - drug therapy
Carcinoma, Renal Cell - pathology
Carcinoma, Renal Cell - physiopathology
Carcinoma, Renal Cell - surgery
Cohort Studies
Diabetes
Diabetes Mellitus - drug therapy
Diabetes Mellitus - physiopathology
Female
Humans
Hypoglycemic Agents - therapeutic use
Kidney Neoplasms - drug therapy
Kidney Neoplasms - pathology
Kidney Neoplasms - physiopathology
Kidney Neoplasms - surgery
Male
Metformin
Metformin - therapeutic use
Middle Aged
Mortality
Recurrence
Renal cell carcinoma
Retrospective Studies
Treatment Outcome
Urology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Introduction Metformin inhibits renal cell carcinoma (RCC) cell proliferation both in vitro and in vivo; however, clinical data regarding the effect of metformin in patients with RCC are lacking. We evaluated the association of metformin use with outcomes among patients with surgically treated localized RCC. Materials and methods We identified 283 consecutive diabetic patients treated surgically for localized RCC between January 1, 1994 and December 31, 2008. Clinicopathologic features were compared between patients exposed to metformin ( n = 83, 29%) and those who were not ( n = 200, 71%). Progression-free, cancer-specific, and overall survival rates were estimated with the Kaplan-Meier analysis, and Cox models were used to evaluate the association of metformin use with outcomes. Results and conclusions Patients receiving metformin had a better renal function (median estimated glomerular filtration rate = 65 vs. 55 ml/min/1.73 m2 , P
ISSN:1078-1439
1873-2496
DOI:10.1016/j.urolonc.2014.07.008